Startseite Kongressberichte & Archiv ASCO Annual Meeting 2017 ASCO Press Conferences ASCO Annual Meeting 2017 Presscast June 3 Part 1

ASCO Annual Meeting 2017 Presscast June 3 Part 1

This presscast below has been produced by ASCO. According to the ASCO press release the following studies have been presented in the Saturday June 3 “News of the Day” Part 1 Briefing:

  • Safety of pregnancy in patients (pts) with history of estrogen receptor positive (ER+) breast cancer (BC): Long-term follow-up analysis from a multicenter study (Abstract  LBA10066) (presscast presentation starts at min 1:11 )                                                                                                                    The autors conclude that this is the largest study addressing the safety of pregnancy in pts with history of ER+ BC. Long-term follow-up confirms that pregnancy is safe and should not be discouraged irrespective of ER status. Our results further strengthen the rationale of the ongoing IBCSG-BIG-NABCG POSITIVE trial (NCT02308085) addressing the role of temporary interruption of adjuvant endocrine therapy to allow pregnancy. Read the full release.
  • LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednison or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer (Abstract  LBA3)                                                                                 (presscast presentation starts at min 9:21)
    The autors conclude that early use of AA+P added to ADT in pts with high-risk mHNPC yielded significantly improved OS, rPFS, and all secondary end points vs ADT+PBOs alone. ADT+AA+P had a favorable risk/benefit ratio and supports early intervention with AA+P in newly diagnosed, high-risk mHNPC. . Read the full release.
     
  • Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476) (Abstract  LBA5003)    (presscast presentation starts at min 17:43)
    The autors conclude that The results show a clinically & statistically significant effect on overall survival & failure-free survival from adding abiraterone at start of ADT with a manageable increase in toxicity. ADT (+/- RT) + abiraterone is a new standard of care for this group. Read the full release.